Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2023)
28 slides from Csl's shareholder meeting presentation, Oct 11, 2023
Slide 1: CSL Limited Annual General Meeting 2023
For immediate release 11 October 2023 CSL LIMITED ANNUAL GENERAL MEETING 2023 For personal use only Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the Chair and Chief Executive Office addresses to shareholders ahead of CSL Limited’s Annual General Meeting, which will be held
Slide 2: Chair Address at the 2023 CSL Annual General Meeting
Chair Address at the 2023 CSL Annual General Meeting Good morning Ladies and Gentlemen. Thank you for joining us today. There is a quorum present and I am delighted to open the meeting. I would now like to introduce your Board of Directors and our Company Secretary. To my right: • Ms Fiona Mead, our
Slide 3: For personal use only
recently stepped down from her position as a Non-executive Director at Aurizon Holdings after nearly nine years’ service. She currently holds two Non-executive Director positions at leading Australian listed entities. These include: • Nine Entertainment Co. Holdings, where she is Chair of the Audit
Slide 4: For personal use only
With these factors in mind, I’d like to address CSL’s recent share price performance, which is a topic close to everyone’s heart. There are several reasons for the weakness we have seen. The macro factors I’ve mentioned have impacted financial markets around the world and CSL has not been immune. Th
Slide 5: For personal use only
There are several reasons for my optimism. The first is the technology available to us. Innovation is based on testing ideas. This can take many years, and often, decades. But with advances in technology, we have been able to slowly close the time taken from hypothesis to experimentation to conclusi
Slide 6: For personal use only
Through an intense and unrelenting focus on our strategy, we have grown from a small, domestic entity who was irrelevant on the global stage, to a truly global biotech company that leads in the sectors we compete in. The “old formula” that led to this exceptional growth is no less relevant today. We
Slide 7: CEO and Managing Director Address at the 2023 CSL AGM
CEO and Managing Director Address at the 2023 CSL Annual General Meeting Thank you Brian and good morning to everyone. Thank you for joining us today for CSL’s 2023 AGM. I am honoured to be addressing you at my first AGM as CEO and Managing Director of CSL. This particular location is close to what
Slide 8: For personal use only
• CSL Seqirus has continued to deliver strong sales growth, driven by its differentiated portfolio, and in particular, by FLUCELVAX. We also announced a license agreement with Arcturus Therapeutics to access their next-generation mRNA vaccine technology. • And for CSL Vifor, we successfully closed t
Slide 9: For personal use only
Cost per litre is around 17% off the peak, so we are making genuine inroads, but there is more to do and it’s just going to take some time. New Products There are numerous exciting opportunities across CSL’s R&D pipeline. We have a number of late-stage R&D programs that are approaching fruition. The
Slide 10: R&D Highlights
R&D Highlights Our R&D portfolio underpins the future of CSL – and our pipeline has several exciting opportunities in late-stage clinical trials, and approaching regulatory approvals. A few highlights: • We achieved a significant milestone with the last patient enrolled in our CSL 112 Phase 3 trial.
Slide 11: For personal use only
For CSL Seqirus: • We anticipate another strong year with continued growth driven by demand for its differentiated portfolio of innovative products. • CSL Seqirus is also progressing global registrations for its next-generation mRNA COVID vaccine. In terms of our guidance for FY24: • We expect reven
Slide 12: Welcome to CSL's 2023 Annual General Meeting
For personal use only CSL Limited Welcome to CSL’s 2023 Annual General Meeting Please ensure your mobile is on silent mode
Slide 13: Address from the Chair
Address from the Chair For personal use only Dr Brian McNamee AO Chair and Independent Non-Executive Director 2
Slide 14: Opening of the new Base Fractionation Facility
For personal use only Opening of the new Base Fractionation Facility Broadmeadows, Australia 3
Slide 15: Marburg, Germany
For personal use only 4 Marburg, Germany
Slide 16: CSL Global HQ & Centre for R&D
For personal use only CSL Global HQ & Centre for R&D Parkville, Australia 5
Slide 17: Our Purpose
Our Purpose The people and science of For personal use only CSL save lives. We develop and deliver innovative medicines that help people with serious and life- threatening conditions live full lives and protect the health of communities around the world. 6
Slide 18: Sustainability Strategy
Sustainability Strategy For personal use only 7
Slide 19: Track record of growth over three decades
Track record of growth over three decades CAGR (%) / First year as an ASX entity1 FY23 multiple (x) 1,350 ~2,750 For personal use only Australia/NZ Employees 24x Rest of World 0 ~30,000 Revenue $143 m $13.31 bn 17% Australia ~95% 8% Revenue by region Rest of World >5% 92% Research & Development spen
Slide 20: Address from CEO and Managing Director
Address from CEO and Managing Director For personal use only Paul McKenzie CEO and Managing Director 9
Slide 21: For personal use only
For personal use only Paul McKenzie CEO and Managing Director Donating plasma using the new Rika device. Visiting the Genesis II team in Bern, Switzerland. 10
Slide 22: Legal Notice
Legal Notice IMPORTANT NOTICE AND DISCLAIMER For personal use only This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form onl
Slide 23: Strong profit growth in FY23
Strong profit growth in FY23 CSL Behring Revenue For personal use only • Strong Ig growth • Record plasma collections $9.29b +12%1 • Successful launch of gene therapy HEMGENIX® CSL Seqirus TOTAL REVENUE • Strong growth in FLUCELVAX® Revenue $13.3b +31%1 • Licence agreement for $2.03b next-generation
Slide 24: CSL Behring Gross Margin Key Contributors
CSL Behring Gross Margin For personal use only Cost Per Litre Reduction Path to margin recovery different to COVID driven Key Contributors1 margin decline New Products2 Anticipate margin to return to pre-COVID level within Average Selling Price Mix Shift 3 – 5 years FX impacts margin given Ig Yield
Slide 25: R&D Highlights – FY23
R&D Highlights – FY23 Transplant For personal use only Immunology Respiratory • Garadacimab (Anti-FXIIa) HAE • CSL787 (Neb Ig) Phase I study enrolment complete • CSL964 (AAT) treatment of GvHD – Phase III study ‒ Phase III study data announced last patient in ‒ Preparations for global regulatory sub
Slide 26: FY24 Outlook
FY24 Outlook1 Strong mid-term outlook Promising cluster of R&D programs nearing completion For personal use only CSL Behring CSL Vifor CSL Seqirus • Strong Ig growth following • Investing in Iron • Continued growth record FY23 plasma to win in an from Influenza collections evolving market vaccine di
Slide 27: CSL's 2030 Strategy
CSL’s 2030 Strategy For personal use only 16
Slide 28: Priorities
For personal use only 17 Priorities